145 related articles for article (PubMed ID: 19296137)
1. Susceptibility of clinical isolates of frequently encountered bacterial species to tigecycline one year after the introduction of this new class of antibiotics: results of the second multicentre surveillance trial in Germany (G-TEST II, 2007).
Kresken M; Leitner E; Seifert H; Peters G; von Eiff C
Eur J Clin Microbiol Infect Dis; 2009 Aug; 28(8):1007-11. PubMed ID: 19296137
[TBL] [Abstract][Full Text] [Related]
2. Resistance trends and in vitro activity of tigecycline and 17 other antimicrobial agents against Gram-positive and Gram-negative organisms, including multidrug-resistant pathogens, in Germany.
Kresken M; Becker K; Seifert H; Leitner E; Körber-Irrgang B; von Eiff C; Löschmann PA;
Eur J Clin Microbiol Infect Dis; 2011 Sep; 30(9):1095-103. PubMed ID: 21347680
[TBL] [Abstract][Full Text] [Related]
3. Susceptibility of common aerobic pathogens to tigecycline: results of a surveillance study in Germany.
Kresken M; Leitner E; Brauers J; Geiss HK; Halle E; von Eiff C; Peters G; Seifert H;
Eur J Clin Microbiol Infect Dis; 2009 Jan; 28(1):83-90. PubMed ID: 18716808
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
Zhang Z; Chen M; Yu Y; Pan S; Liu Y
Antimicrob Resist Infect Control; 2018; 7():152. PubMed ID: 30564308
[TBL] [Abstract][Full Text] [Related]
5. Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004-2013.
Hoban DJ; Reinert RR; Bouchillon SK; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2015 May; 14():27. PubMed ID: 25958201
[TBL] [Abstract][Full Text] [Related]
6. Antimicrobial susceptibility among Gram-positive organisms collected from pediatric patients globally between 2004 and 2011: results from the Tigecycline Evaluation and Surveillance Trial.
Brandon M; Dowzicky MJ
J Clin Microbiol; 2013 Jul; 51(7):2371-8. PubMed ID: 23678070
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
Vega S; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
Kanj SS; Whitelaw A; Dowzicky MJ
Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010.
Balode A; Punda-Polić V; Dowzicky MJ
Int J Antimicrob Agents; 2013 Jun; 41(6):527-35. PubMed ID: 23590898
[TBL] [Abstract][Full Text] [Related]
10. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).
Pfaller MA; Huband MD; Streit JM; Flamm RK; Sader HS
Int J Antimicrob Agents; 2018 Jun; 51(6):848-853. PubMed ID: 29410368
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
[TBL] [Abstract][Full Text] [Related]
12. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
Dowzicky MJ; Park CH
Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
[TBL] [Abstract][Full Text] [Related]
13. Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011-2014).
Sader HS; Castanheira M; Farrell DJ; Flamm RK; Mendes RE; Jones RN
Int J Antimicrob Agents; 2016 Aug; 48(2):144-50. PubMed ID: 27291285
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of tigecycline against isolates collected from complicated skin and skin structure infections and intra-abdominal infections in Africa and Middle East countries: TEST 2007-2012.
Renteria MI; Biedenbach DJ; Bouchillon SK; Hoban DJ; Raghubir N; Sajben P; Mokaddas E
Diagn Microbiol Infect Dis; 2014 May; 79(1):54-9. PubMed ID: 24582580
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in Spain, 2004-2014.
Marco F; Dowzicky MJ
J Glob Antimicrob Resist; 2016 Sep; 6():50-56. PubMed ID: 27530839
[TBL] [Abstract][Full Text] [Related]
16. A longitudinal analysis of antimicrobial susceptibility in clinical institutions in Germany as part of the Tigecycline Evaluation and Surveillance Trial (2004-2007).
Seifert H; Dowzicky MJ
Chemotherapy; 2009; 55(4):241-52. PubMed ID: 19468222
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial.
Morfin-Otero R; Noriega ER; Dowzicky MJ
Ann Clin Microbiol Antimicrob; 2015 Dec; 14():53. PubMed ID: 26667651
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of tigecycline activity in clinical isolates among Indian medical centers.
Manoharan A; Chatterjee S; Madhan S; Mathai D
Indian J Pathol Microbiol; 2010; 53(4):734-7. PubMed ID: 21045403
[TBL] [Abstract][Full Text] [Related]
19. Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010.
Liu JW; Ko WC; Huang CH; Liao CH; Lu CT; Chuang YC; Tsao SM; Chen YS; Liu YC; Chen WY; Jang TN; Lin HC; Chen CM; Shi ZY; Pan SC; Yang JL; Kung HC; Liu CE; Cheng YJ; Chen YH; Lu PL; Sun W; Wang LS; Yu KW; Chiang PC; Lee MH; Lee CM; Hsu GJ; Hsueh PR
Antimicrob Agents Chemother; 2012 Mar; 56(3):1414-7. PubMed ID: 22155819
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility of Gram-negative and Gram-positive bacteria collected from Eastern Europe: Results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2011-2016.
Dowzicky MJ; Chmelařová E
J Glob Antimicrob Resist; 2019 Jun; 17():44-52. PubMed ID: 30445209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
